Choreo LLC Has $1.78 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Choreo LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 109.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,354 shares of the medical research company’s stock after acquiring an additional 1,755 shares during the quarter. Choreo LLC’s holdings in Thermo Fisher Scientific were worth $1,781,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. McAdam LLC acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $210,000. Mather Group LLC. increased its position in Thermo Fisher Scientific by 5.6% during the 4th quarter. Mather Group LLC. now owns 3,099 shares of the medical research company’s stock valued at $1,645,000 after purchasing an additional 163 shares during the period. Monumental Financial Group Inc. increased its position in Thermo Fisher Scientific by 4.6% during the 4th quarter. Monumental Financial Group Inc. now owns 2,196 shares of the medical research company’s stock valued at $1,166,000 after purchasing an additional 96 shares during the period. Silver Oak Securities Incorporated acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $240,000. Finally, Magnus Financial Group LLC increased its position in Thermo Fisher Scientific by 2.9% during the 4th quarter. Magnus Financial Group LLC now owns 3,076 shares of the medical research company’s stock valued at $1,633,000 after purchasing an additional 88 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on TMO. Deutsche Bank Aktiengesellschaft increased their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Barclays increased their price target on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a report on Thursday, April 25th. The Goldman Sachs Group increased their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Evercore ISI increased their price target on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Finally, Citigroup began coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price target on the stock. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $607.35.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $568.74 on Wednesday. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. The stock’s fifty day simple moving average is $574.58 and its two-hundred day simple moving average is $531.67. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The stock has a market cap of $217.09 billion, a PE ratio of 36.48, a price-to-earnings-growth ratio of 2.40 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The business had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 21.59 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Insider Activity

In other news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The disclosure for this sale can be found here. Insiders sold a total of 52,277 shares of company stock valued at $29,649,264 in the last ninety days. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.